Fresenius Medical Care (NYSE:FMS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report sent to investors on Saturday morning. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial decreased their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a hold rating on the stock in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $22.00.

Fresenius Medical Care Stock Down 0.7 %

Shares of NYSE FMS opened at $20.94 on Friday. The company’s 50-day simple moving average is $19.48 and its 200-day simple moving average is $19.90. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $23.29. The firm has a market cap of $12.29 billion, a price-to-earnings ratio of 23.53, a price-to-earnings-growth ratio of 1.09 and a beta of 0.90. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting the consensus estimate of $0.38. The firm had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Equities analysts predict that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors have recently bought and sold shares of FMS. Corient Private Wealth LLC raised its stake in Fresenius Medical Care by 164.6% during the fourth quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock worth $1,378,000 after purchasing an additional 41,139 shares during the period. Assetmark Inc. raised its stake in Fresenius Medical Care by 169.9% during the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after purchasing an additional 2,630 shares during the period. Morningstar Investment Services LLC raised its stake in shares of Fresenius Medical Care by 104.3% in the 4th quarter. Morningstar Investment Services LLC now owns 20,729 shares of the company’s stock valued at $434,000 after acquiring an additional 10,584 shares during the period. GAMMA Investing LLC raised its stake in shares of Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after acquiring an additional 758 shares during the period. Finally, Uncommon Cents Investing LLC raised its stake in shares of Fresenius Medical Care by 8.0% in the 1st quarter. Uncommon Cents Investing LLC now owns 38,810 shares of the company’s stock valued at $748,000 after acquiring an additional 2,890 shares during the period. 8.25% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.